| Bioshares

Categories

ARX1

February 20th, 2026

Aroa Biosurgery Update

ACW2

February 20th, 2026

Actinogen Medical 'Increasingly Confident of Positive Outcome'

CGS2

February 20th, 2026

Cogstate Half Year Results

CGS1

January 30th, 2026

Cogstate - Half Year Update, Record Level of New Sales Opportunities

ACW1

January 30th, 2026

Actinogen Medical Gets Green Light from Data Monitoring Committee

CGS

December 23rd, 2025

Cogstate - "Record Level of Opportunities"

CUV1

December 23rd, 2025

Bioshares Top 6 Picks for 2026: Clinuvel Pharmaceuticals - First Phase III Trial Readout in Vitiligo

SNT1

December 23rd, 2025

Top 6 Pick: Syntara - 5 Clinical Study Readouts in 2026

December 23rd, 2025

Top 6 Picks for 2026: Transformative Year Ahead for Cynata Therapeutics

CUV

December 16th, 2025

Clinuvel Pharmaceuticals to File ACTH Generic for Approval in 2026 for Billion Dollar Market

CC5

December 16th, 2025

Clever Culture Systems - Positioned for Strong Growth and Profitability

SNT2

December 16th, 2025

Syntara's Clever Phase Ib Skin Scarring Study in 2026 to Address 'Enormous' Market Opportunity

IMU

December 16th, 2025

Imugene Gets Clear Direction from FDA to Move into Pivotal Study

ACW

December 16th, 2025

Actinogen Medical - Good Rational for Positive Trial Outcome in 2026

CHM

November 21st, 2025

Chimeric Therapeutics - Stable Disease in Cohort 2

IMU2

November 21st, 2025

Imugene Prioritises Azer-Cel Program; Reduces Internal Drug Development

ARX2

October 28th, 2025

Aroa Biosurgery Delivers 4th Consecutive Positive Cashflow Quarter

CGS

October 28th, 2025

Second Best Quarter of Sales for Cogstate

BB1

October 28th, 2025

Robust Results for Blinklab Paves Way for Registrational Autism Study

1637040346498Copy_of_CEO_TEMPLATES_MAKE_DUPLICATES

October 13th, 2025

Clinical Trial Progress: Imugene Data Continues to Impress

Pages

1
2
3
4
5
6
7
8
9
10